ReviewJournal of clinical medicine2020
Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime?
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Radiation meets inflammation: NLRP3 inflammasome at the core of radiation-induced cardiac injury.Journal of translational medicine · 2025Review
- Cardiovascular disease in breast cancer patients: a nationwide real-world evidence study 2013-20.European heart journal open · 2025Article
- Prevention of cancer-therapy related cardiac dysfunction.Current heart failure reports · 2025Review
- Exercise as Medicine in Cardio-Oncology: Reducing Health Disparities in Hispanic and Latina Breast Cancer Survivors.Current oncology reports · 2023Review
- Echocardiographic strategy for early detection of cardiotoxicity of doxorubicin: a prospective observational study.Cardio-oncology (London, England) · 2022Article
- Subclinical cardiac damage in cancer patients before chemotherapy.Heart failure reviews · 2022Review
- MiRNAs and circRNAs for the Diagnosis of Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients: A Narrative Review.Journal of personalized medicine · 2022Review
- In-hospital mortality, length of stay and hospital costs for hospitalized breast cancer patients with comorbid heart failure in the USA.Current medical research and opinion · 2021Article
- Exercise to Reduce Anthracycline-Mediated Cardiovascular Complications in Breast Cancer Survivors.Current oncology (Toronto, Ont.) · 2021Review
- Steroid Receptors in Breast Cancer: Understanding of Molecular Function as a Basis for Effective Therapy Development.Cancers · 2021Review
- Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer.Current oncology reports · 2021Review
- Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer.Molecular and cellular biochemistry · 2021Review
- Breast Radiotherapy-Related Cardiotoxicity. When, How, Why. Risk Prevention and Control Strategies.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardio-oncology is an emerging field tasked with identifying and treating cancer therapy related cardiac dysfunction (e.g., cytotoxic agents, immunotherapies, radiation, and hormone therapies) and optimizing the cardiovascular health of cancer patients exposed to these agents. Novel cancer therapies have led to significant improvements in clinical outcomes for breast cancer patients. In this article, we review the current literature on assessing cardiovascular risk of breast cancer therapies and discuss strategies (including pharmacological and lifestyle interventions) to prevent cardiovascular toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.